Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,950 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Gemcitabine | US FDA | Malignant Pancreatic Neoplasm | as a single agent for the treatment of pancreatic cancer. | approved | Aug 4, 2011 | openfda |
| Gemcitabine | US FDA | Lung Non-Small Cell Carcinoma | in combination with cisplatin for the treatment of non-small cell lung cancer. | approved | Aug 4, 2011 | openfda |
| Gemcitabine | US FDA | Malignant Breast Neoplasm | in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. | approved | Aug 4, 2011 | openfda |
| Gemtuzumab Ozogamicin | EU EMA | Acute Promyelocytic Leukemia | Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL). | approved | Apr 19, 2018 | ema |
| Gemtuzumab Ozogamicin | US FDA | Acute Myeloid Leukemia | treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older | approved | Sep 1, 2017 | openfda |
| Gemtuzumab Ozogamicin | US FDA | Acute Myeloid Leukemia | treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older | approved | Sep 1, 2017 | openfda |
| Gilteritinib | EU EMA | Acute Myeloid Leukemia | Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. | approved | Oct 24, 2019 | ema |
| Gilteritinib | US FDA | Acute Myeloid Leukemia | XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. | approved | Nov 28, 2018 | openfda |
| Glasdegib | EU EMA | Secondary Acute Myeloid Leukemia | Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy. | approved | Jun 26, 2020 | ema |
| Glasdegib | US FDA | Acute Myeloid Leukemia | DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1 ) | approved | Nov 21, 2018 | openfda |
| Glofitamab | EU EMA | Diffuse Large B-Cell Lymphoma | Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy. | approved | Jul 7, 2023 | ema |
| Goserelin | US FDA | Prostate Carcinoma | Use as palliative treatment of advanced carcinoma of the prostate | approved | Jan 11, 1996 | openfda |
| Goserelin | US FDA | Prostate Carcinoma | Use in combination with flutamide for the management of locally confined carcinoma of the prostate | approved | Jan 11, 1996 | openfda |
| Goserelin | US FDA | Malignant Breast Neoplasm | Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women | approved | Dec 29, 1989 | openfda |
| Goserelin | US FDA | Prostate Carcinoma | Use in combination with flutamide for the management of locally confined carcinoma of the prostate | approved | Dec 29, 1989 | openfda |
| Goserelin | US FDA | Prostate Carcinoma | Palliative treatment of advanced carcinoma of the prostate | approved | Dec 29, 1989 | openfda |
| Histamine | EU EMA | Acute Myeloid Leukemia | Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60. | approved | Oct 7, 2008 | ema |
| Histrelin | US FDA | Conventional Osteosarcoma | SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. SUPPRELIN LA is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of children with central precocious puberty (CPP) ( 1 ). | approved | May 3, 2007 | openfda |
| Ibritumomab Tiuxetan | EU EMA | Follicular Lymphoma | Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). | withdrawnsince Jan 4, 2024 | Jan 16, 2004 | ema |
| Ibritumomab Tiuxetan | US FDA | B-Cell Non-Hodgkin Lymphoma | relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) | approved | Feb 19, 2002 | openfda |
| Ibrutinib | US FDA | Waldenstrom Macroglobulinemia | . Adult patients with Waldenström’s macroglobulinemia (WM) | approved | Aug 24, 2022 | openfda |
| Ibrutinib | US FDA | Waldenstrom Macroglobulinemia | . Adult patients with Waldenström’s macroglobulinemia (WM) | approved | Feb 16, 2018 | openfda |
| Ibrutinib | US FDA | Waldenstrom Macroglobulinemia | . Adult patients with Waldenström’s macroglobulinemia (WM) | approved | Feb 16, 2018 | openfda |
| Ibrutinib | US FDA | Waldenstrom Macroglobulinemia | . Adult patients with Waldenström’s macroglobulinemia (WM) | approved | Feb 12, 2014 | openfda |
| Ibrutinib | US FDA | Waldenstrom Macroglobulinemia | . Adult patients with Waldenström’s macroglobulinemia (WM) | approved | Nov 13, 2013 | openfda |
| Idarubicin | US FDA | Acute Myeloid Leukemia | IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1) | approved | Feb 17, 1997 | openfda |
| Idecabtagene Vicleucel | EU EMA | Multiple Myeloma | Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy. | approved | Aug 18, 2021 | ema |
| Ifosfamide | US FDA | Malignant Testicular Neoplasm | Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. Ifosfamide for Injection is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. ( 1 ) | approved | Aug 14, 1987 | openfda |
| Imatinib | US FDA | Malignant Gastrointestinal Stromal Tumor | Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Acute Lymphoblastic Leukemia | Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Acute Lymphoblastic Leukemia | Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Aggressive Systemic Mastocytosis | Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Myelodysplastic/Myeloproliferative Neoplasm | Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. | approved | Nov 22, 2024 | openfda |
| Imatinib | US FDA | Aggressive Systemic Mastocytosis | Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. | approved | Apr 18, 2003 | openfda |
| Imatinib | US FDA | Acute Lymphoblastic Leukemia | Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). | approved | Apr 18, 2003 | openfda |
| Imatinib | US FDA | Malignant Gastrointestinal Stromal Tumor | Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). | approved | Apr 18, 2003 | openfda |
| Imatinib | US FDA | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. | approved | Apr 18, 2003 | openfda |
| Imatinib | US FDA | Acute Lymphoblastic Leukemia | Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. | approved | Apr 18, 2003 | openfda |
| Imatinib | US FDA | Myelodysplastic/Myeloproliferative Neoplasm | Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Malignant Gastrointestinal Stromal Tumor | Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Aggressive Systemic Mastocytosis | Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Acute Lymphoblastic Leukemia | Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Myelodysplastic/Myeloproliferative Neoplasm | Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. | approved | Apr 18, 2003 | openfda |
| Imatinib Mesylate | US FDA | Acute Lymphoblastic Leukemia | Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. | approved | Apr 18, 2003 | openfda |
| Imiquimod | EU EMA | Superficial Basal Cell Carcinoma | Imiquimod cream is indicated for the topical treatment of : External genital and perianal warts (condylomata acuminata) in adults. Small superficial basal cell carcinomas (sBCCs) in adults. Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. | approved | Sep 18, 1998 | ema |
| Imlunestrant | EU EMA | Malignant Breast Neoplasm | Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2).In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. | approved | Jan 9, 2026 | ema |
| Imlunestrant | US FDA | Malignant Breast Neoplasm | INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 ) | approved | Sep 25, 2025 | openfda |
| Inavolisib | EU EMA | Malignant Breast Neoplasm | Itovebi, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment (see section 5.1). Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist. | approved | Jul 18, 2025 | ema |
Data updated 2 days agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 403 | 92 | 310 |
| Dasatinib | 313 | 179 | 134 |
| Imatinib | 274 | 144 | 130 |
| Erlotinib | 268 | 174 | 94 |
| Crizotinib | 262 | 141 | 121 |
| Vemurafenib | 261 | 149 | 111 |
| Gefitinib | 185 | 142 | 43 |
| Sunitinib | 164 | 91 | 72 |
| Trametinib | 157 | 129 | 28 |
| Afatinib | 129 | 120 | 9 |
| Panitumumab | 127 | 34 | 93 |
| Trastuzumab | 127 | 90 | 37 |
| Olaparib | 108 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 105 |
| 3 |
| Dabrafenib | 107 | 74 | 33 |
| Imatinib Mesylate | 100 | 20 | 80 |
| Sorafenib | 95 | 72 | 23 |
| Bosutinib | 91 | 32 | 59 |
| Lapatinib | 85 | 64 | 21 |
| Selumetinib | 85 | 71 | 14 |
| Palbociclib | 84 | 75 | 9 |
| Larotrectinib | 79 | 63 | 16 |
| Cisplatin | 77 | 45 | 31 |
| Entrectinib | 69 | 62 | 7 |
| Ponatinib | 67 | 56 | 11 |
| Nilotinib | 65 | 20 | 45 |
| Osimertinib | 62 | 48 | 14 |
| Chemotherapy | 61 | 39 | 22 |
| Axitinib | 57 | 17 | 40 |
| Erdafitinib | 54 | 51 | 3 |
| Dactolisib | 53 | 44 | 9 |
| Pembrolizumab | 53 | 38 | 12 |
| Bevacizumab | 45 | 33 | 12 |
| Irinotecan | 44 | 12 | 32 |
| Fluorouracil | 43 | 28 | 12 |
| Gemcitabine | 43 | 29 | 13 |
| Neratinib | 43 | 40 | 3 |
| Regorafenib Anhydrous | 43 | 24 | 19 |
| Selpercatinib | 43 | 34 | 9 |
| Doxorubicin | 41 | 9 | 32 |
| Alectinib | 40 | 18 | 22 |
| Ceritinib | 40 | 27 | 13 |
| Everolimus | 39 | 34 | 4 |
| Carboplatin | 38 | 29 | 9 |
| Venetoclax | 37 | 4 | 33 |
| Fulvestrant | 35 | 30 | 5 |
| Paclitaxel | 35 | 21 | 13 |
| Vismodegib | 35 | 9 | 26 |
| Midostaurin | 33 | 28 | 4 |
| Futibatinib | 32 | 29 | 3 |
| Mercaptopurine | 31 | 2 | 28 |
| Rucaparib | 31 | 31 | 0 |
| Infigratinib | 30 | 26 | 4 |
| Sirolimus | 30 | 25 | 5 |
| Docetaxel | 29 | 20 | 9 |
| Nivolumab | 29 | 20 | 6 |
| Thioguanine | 29 | 0 | 28 |
| Lorlatinib | 28 | 21 | 7 |
| Atezolizumab | 26 | 21 | 3 |
| Pazopanib | 26 | 25 | 1 |
| Pictilisib | 26 | 25 | 1 |
| Melphalan | 25 | 1 | 24 |
| Binimetinib | 24 | 23 | 1 |
| Pertuzumab | 24 | 24 | 0 |
| Tazemetostat | 24 | 24 | 0 |
| Trastuzumab Deruxtecan | 24 | 24 | 0 |
| MDM2 Inhibitor AMGMDS3 | 23 | 1 | 22 |
| Talazoparib | 23 | 23 | 0 |
| Temozolomide | 23 | 20 | 3 |
| Capivasertib | 22 | 21 | 1 |
| Crenolanib | 22 | 21 | 1 |
| Oxaliplatin | 22 | 6 | 16 |
| Quizartinib | 22 | 13 | 8 |
| BRAF Inhibitor | 21 | 21 | 0 |
| Brigatinib | 21 | 12 | 9 |
| Gilteritinib | 21 | 18 | 3 |
| Alpelisib | 20 | 15 | 5 |
| Cobimetinib | 20 | 20 | 0 |
| Enzalutamide | 20 | 8 | 12 |
| Aspirin | 19 | 19 | 0 |
| Regorafenib | 19 | 12 | 7 |
| Tamoxifen | 19 | 11 | 8 |
| Trastuzumab Emtansine | 19 | 10 | 9 |
| Cabozantinib | 18 | 17 | 1 |
| Capecitabine | 18 | 11 | 4 |
| Capmatinib | 18 | 15 | 1 |
| Sotorasib | 18 | 17 | 0 |
| Cytarabine | 17 | 5 | 12 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 17 | 15 | 2 |
| Pralsetinib | 17 | 11 | 6 |
| Dacomitinib | 16 | 15 | 1 |
| Immune Checkpoint Inhibitor | 16 | 13 | 2 |
| Ivosidenib | 16 | 16 | 0 |
| Lestaurtinib | 16 | 15 | 1 |
| Pemetrexed | 16 | 11 | 5 |
| PI103 | 16 | 16 | 0 |
| Temsirolimus | 16 | 15 | 1 |
| ALK Inhibitor TAE684 | 15 | 12 | 3 |
| Daunorubicin | 15 | 4 | 11 |
| Tepotinib | 15 | 15 | 0 |
| Abiraterone | 14 | 3 | 11 |
| Encorafenib | 14 | 13 | 1 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 14 | 10 | 4 |
| Methotrexate | 14 | 2 | 9 |
| Pexidartinib | 14 | 6 | 8 |
| Platinum Compound | 14 | 13 | 1 |
| Tretinoin | 14 | 8 | 6 |
| Bafetinib | 13 | 1 | 12 |
| Dovitinib | 13 | 13 | 0 |
| Ruxolitinib | 13 | 13 | 0 |
| Ibrutinib | 12 | 6 | 6 |
| Prednisone | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Durvalumab | 11 | 10 | 1 |
| Mirdametinib | 11 | 9 | 2 |
| PD173074 | 11 | 10 | 1 |
| Revumenib | 11 | 4 | 7 |
| Akt Inhibitor MK2206 | 10 | 9 | 1 |
| Asparaginase | 10 | 0 | 10 |
| Etoposide | 10 | 7 | 3 |
| Fexagratinib | 10 | 9 | 1 |
| PLX4720 | 10 | 5 | 4 |
| R3Mab | 10 | 5 | 5 |
| JQ1 | 9 | 9 | 0 |
| PI3Ka/Di | 9 | 7 | 2 |
| Vandetanib | 9 | 8 | 1 |
| Inavolisib | 8 | 8 | 0 |
| Ipilimumab | 8 | 6 | 1 |
| MEK Inhibitor CI-1040 | 8 | 8 | 0 |
| Niraparib | 8 | 8 | 0 |
| Panobinostat | 8 | 7 | 1 |
| Ribociclib | 8 | 5 | 3 |
| Vorinostat | 8 | 7 | 1 |
| Azacitidine | 7 | 7 | 0 |
| Foretinib | 7 | 6 | 1 |
| GSK126 | 7 | 7 | 0 |
| Mitomycin | 7 | 6 | 1 |
| MTOR Inhibitor | 7 | 7 | 0 |
| Multikinase Inhibitor AEE788 | 7 | 5 | 2 |
| Pemigatinib | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Repotrectinib | 7 | 7 | 0 |
| Sonidegib | 7 | 4 | 3 |
| Sunvozertinib | 7 | 7 | 0 |
| Taselisib | 7 | 6 | 1 |
| VTP-50469 | 7 | 0 | 7 |
| Arsenic Trioxide | 6 | 3 | 3 |
| AZD3463 | 6 | 1 | 5 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Dinaciclib | 6 | 5 | 1 |
| Ipilimumab/Nivolumab Regimen | 6 | 6 | 0 |
| Linsitinib | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 6 | 6 | 0 |
| Radiation Therapy | 6 | 4 | 2 |
| Sapanisertib | 6 | 6 | 0 |
| Tanespimycin | 6 | 6 | 0 |
| Trabectedin | 6 | 6 | 0 |
| Veliparib | 6 | 6 | 0 |
| Adavosertib | 5 | 5 | 0 |
| ALK Inhibitor ASP3026 | 5 | 1 | 4 |
| Amivantamab | 5 | 5 | 0 |
| Buparlisib | 5 | 5 | 0 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| MEK Inhibitor RO4987655 | 5 | 1 | 4 |
| Metformin | 5 | 5 | 0 |
| MTOR Kinase Inhibitor PP242 | 5 | 4 | 1 |
| PD1 Inhibitor | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Adagrasib | 4 | 4 | 0 |
| Anti-PD1 Monoclonal Antibody | 4 | 3 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 4 | 2 | 2 |
| Apitolisib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| ARS-1620 | 4 | 3 | 0 |
| Asciminib | 4 | 4 | 0 |
| Bicalutamide | 4 | 1 | 3 |
| Decitabine | 4 | 4 | 0 |
| Dordaviprone | 4 | 4 | 0 |
| Duligotuzumab | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| Eprenetapopt | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| JQEZ5 | 4 | 4 | 0 |
| Lenvatinib | 4 | 3 | 1 |
| Letrozole | 4 | 3 | 1 |
| Leucovorin | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 4 | 2 | 2 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 4 | 4 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 4 | 4 | 0 |
| PI3K/BET Inhibitor LY294002 | 4 | 4 | 0 |
| Poziotinib | 4 | 4 | 0 |
| Refametinib | 4 | 3 | 1 |
| Rogaratinib | 4 | 4 | 0 |
| Taxane Compound | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vincristine | 4 | 3 | 1 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| Abiraterone Acetate | 3 | 0 | 3 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ATR Inhibitor | 3 | 3 | 0 |
| Avapritinib | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Birabresib | 3 | 3 | 0 |
| Bortezomib | 3 | 3 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 3 | 3 | 0 |
| Cabazitaxel | 3 | 2 | 1 |
| Canertinib | 3 | 3 | 0 |
| CDK Inhibitor SNS-032 | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dostarlimab | 3 | 3 | 0 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| IGF1R Monoclonal Antibody | 3 | 3 | 0 |
| Immunotherapy | 3 | 3 | 0 |
| Ipatasertib | 3 | 3 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Mobocertinib | 3 | 3 | 0 |
| PD98059 | 3 | 1 | 2 |
| Perifosine | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| RapaLink-1 | 3 | 1 | 2 |
| RDEA 119 | 3 | 3 | 0 |
| RG7112 | 3 | 2 | 1 |
| Ridaforolimus | 3 | 2 | 1 |
| Savolitinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tandutinib | 3 | 2 | 1 |
| Tegafur | 3 | 0 | 0 |
| Teprotumumab | 3 | 3 | 0 |
| Tipifarnib | 3 | 3 | 0 |
| Trastuzumab Deruxtecan | 3 | 3 | 0 |
| Tremelimumab | 3 | 3 | 0 |
| Trichostatin A | 3 | 2 | 1 |
| Zongertinib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Alvocidib | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Angiogenesis Inhibitor | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Belinostat | 2 | 0 | 0 |
| BET Inhibitor | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| CDK4/6 Inhibition | 2 | 1 | 1 |
| Cediranib | 2 | 2 | 0 |
| Celecoxib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Chk1 Inhibitor | 2 | 2 | 0 |
| Copanlisib | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| Elimusertib | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ganetespib | 2 | 1 | 1 |
| Ganitumab | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Izorlisib | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Meloxicam | 2 | 2 | 0 |
| Mocetinostat | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Navtemadlin | 2 | 2 | 0 |
| Nimotuzumab | 2 | 2 | 0 |
| Nirogacestat | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| Pidnarulex | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Rebemadlin | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rezatapopt | 2 | 2 | 0 |
| RG7356 | 2 | 1 | 1 |
| Rigosertib | 2 | 0 | 2 |
| Ripretinib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| SAIT301 | 2 | 2 | 0 |
| Salinomycin | 2 | 2 | 0 |
| Salirasib | 2 | 2 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Selitrectinib | 2 | 2 | 0 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tarextumab | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Tovorafenib | 2 | 2 | 0 |
| Triciribine | 2 | 2 | 0 |
| Tucatinib | 2 | 2 | 0 |
| Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Vatalanib | 2 | 2 | 0 |
| Verteporfin | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| ACLY SiRNA | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Afamitresgene Autoleucel | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| Agerafenib | 1 | 1 | 0 |
| AKTi-1/2 | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK/TRK Inhibitor TSR-011 | 1 | 0 | 1 |
| AMG511 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Anvumetostat | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| ARQ092 | 1 | 1 | 0 |
| ARS-853 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD5438 | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAN508 | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carfilzomib | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Chlorambucil | 1 | 1 | 0 |
| Chloroquine | 1 | 1 | 0 |
| CHMFL-KIT-031 | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Cytoreductive Surgery | 1 | 1 | 0 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EFTX-G12V | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Enfortumab Vedotin | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FACT Complex-targeting Curaxin CBL0137 | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FEC Regimen | 1 | 0 | 1 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGFR Inhibitor ASP5878 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| G-573 | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| GDC-0879 | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| GNE-617 | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDAC Inhibitor REC-2282 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HER2 Inhibitor CP-724,714 | 1 | 0 | 1 |
| Hydroxychloroquine | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| Hyperthermic Intraperitoneal Chemotherapy | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Inhibitor | 1 | 1 | 0 |
| Iniparib | 1 | 1 | 0 |
| Interventional Radiology Procedure | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| KG5 | 1 | 0 | 1 |
| KU-0060648 | 1 | 1 | 0 |
| Larotrectinib Regimen | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Leuprolide | 1 | 1 | 0 |
| Lifirafenib | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor GDC-0623 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Niacinamide | 1 | 0 | 1 |
| Nilutamide | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| NU7441 | 1 | 1 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Pan-RAF Inhibitor LY3009120 | 1 | 1 | 0 |
| PARP Inhibitor ABT-888 | 1 | 1 | 0 |
| PARP Inhibitor AZD2461 | 1 | 1 | 0 |
| Pasireotide | 1 | 1 | 0 |
| Patidegib | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-180970 | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pegargiminase | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| RG5 | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Seribantumab | 1 | 1 | 0 |
| Sertraline | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Sorafenib Tosylate | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| TRK Inhibitor | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| VEGF/VEGFR Inhibitors | 1 | 1 | 0 |
| Vociprotafib | 1 | 0 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
| WZ4002 | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.